ContextStatin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and
mortality. However, the optimal strategy and target level for lipid reduction remain uncertain …

Background Statins reduce adverse cardiovascular outcomes and slow the progression of
coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) …

Statins reduce both atherogenic lipoproteins and high-sensitivity C-reactive protein
(hsCRP). The optimal strategy for administration of lipid-lowering agents has evolved …

ContextStatins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow
progression of coronary atherosclerosis. However, no data exist describing the relationship …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

Background Percutaneous coronary revascularization is widely used in improving symptoms
and exercise performance in patients with ischemic heart disease and stable angina …

Background Recent trials have demonstrated better outcomes with intensive than with
moderate statin treatment. Intensive treatment produced greater reductions in both low …

ContextEvidence suggests that more intensive lowering of low-density lipoprotein
cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable …

Aims The impact of baseline coronary plaque burden on the clinical outcome in patients
receiving aggressive low-density lipoprotein cholesterol (LDL-C) lowering therapy to levels< …

Background There is a discrepancy between the marked reduction in adverse events with
statins and their modest effect on atheroma regression. We hypothesized that, in a Western …